Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 2007, p. 4401-4409, Vol. 51, No. 12
0066-4804/07/$08.00+0 doi:10.1128/AAC.00926-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Bacterial Pathogenesis and Infection Control, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan,1 Department of Bacteriology and Bacterial Infection Control, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan2
Received 17 July 2007/ Returned for modification 9 August 2007/ Accepted 3 September 2007
|
|
|---|
|
|
|---|
In 2003, a plasmid-mediated 16S rRNA methyltransferase, which confers a high level of resistance to various clinically important aminoglycosides, was reported to be involved as part of a novel aminoglycoside resistance mechanism in pathogenic gram-negative rods (16, 53). At present, five types of plasmid-mediated 16S rRNA methyltransferase genes, rmtA, rmtB, rmtC, rmtD, and armA, have been found worldwide in members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp. (4, 7, 10, 11, 17, 20, 34, 48, 50-52). Also, these genes are mediated by bacterium-specific recombination systems, such as transposons, and are easily translocated to other DNA target sites (17, 19, 47, 49).
The 16S rRNA methyltransferases conferring aminoglycoside resistance are supposed to have evolved as a self-defense mechanism in aminoglycoside-producing actinomycetes, including Streptomyces spp. and Micromonospora spp (9). The methylation of 16S rRNA plays a crucial role in prevention of the adverse effects of intrinsic aminoglycosides that would block their own 16S rRNA. The 16S rRNA methyltransferase conferring aminoglycoside resistance consists of two different groups, one methylates the N-7 position of G1405 and confers panresistance to aminoglycosides belonging to both the kanamycin and the gentamicin groups (3, 44), and the other methylates the N-1 position of A1408 and provides resistance to kanamycin and apramycin (3, 22, 43). Recently, it was reported that the plasmid-mediated 16S rRNA methyltranferase ArmA methylates the N-7 position of G1405 within 16S rRNA (27). On the other hand, no plasmid-mediated 16S rRNA methyltransferase which modifies the N-1 position of A1408 has so far been found in any pathogenic bacteria isolated from clinical settings and natural environments. Therefore, we screened for a new plasmid-mediated methyltransferase that methylates A1408 among bacterial species belonging to the family Enterobacteriaceae, P. aeruginosa, and Acinetobacter spp. isolated in Japanese clinical settings. Apramycin resistance seemed to be a good indicator for the detection of an A1408 16S rRNA methyltransferase producer, since a previous study reported that the introduction of a recombinant plasmid encoding a gene for the A1408 16S rRNA methyltransferase derived from a Streptomyces sp. was also able to confer a high level of resistance to apramycin (43). The use of this screening protocol on the basis of apramycin resistance allowed us to identify a panaminoglycoside-resistant Escherichia coli strain, strain ARS3, that produces a novel plasmid-mediated methyltransferase, newly assigned NpmA, that methylates A1408 at the A site of 16S rRNA. The aim of this study was to characterize the molecular mechanism underlying the panaminoglycoside resistance conferred by NpmA.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Bacterial strains and plasmids used in this study
|
Cloning of npmA. The transferable plasmid pARS3 was extracted from the E. coli conjugant and digested with restriction enzymes. The resultant fragments were ligated to cloning vectors and electroporated into E. coli strain JM109. The transformants were selected on LB agar plates supplemented with apramycin at 150 µg/ml and chloramphenicol at 30 µg/ml. The npmA gene was amplified with primer P1 (5'-CGG GAT CCA AGC ACT TTC ATA CTG ACG-3') and primer P2 (5'-CGG AAT TCC AAT TTT GTT CTT ATT AGC-3') (the underscored sequences indicate BamHI and EcoRI restriction sites, respectively) and cloned into the vector pMCL210.
N-terminal determination of NpmA. The DNA fragment carrying npmA and its promoter region was amplified by PCR with primers P1 and P3 (the sequence of primer P3 is 5'-CCC AAG CTT TTA atg atg atg atg atg ATG TTT TGA AAC ATG GCC-3' [where the underscores indicate the Hind III restriction site and the sequence with lowercase letters represents the nucleotide sequence of C-terminal histidine tag]). Primer P3 was designed so that five histidine codons could be added to the 3' end of npmA. The resultant fragments were ligated to pMCL210 and introduced into E. coli JM109. The cells were cultured in 1 liter of LB broth containing chloramphenicol at 30 µg/ml, disrupted with a French press, and centrifuged at 100,000 x g for 1 h. The supernatant containing the recombinant protein was loaded onto a HisTrap HP column (Amersham Biosciences) and purified according to the manufacturer's instructions. The N-terminal sequence of the purified protein was obtained by Edman degradation in a model Shimadzu PPSQ-23 automated protein sequencer.
Overexpression and purification of histidine-tagged NpmA. The npmA gene was amplified with primer P4 (5'-GGA ATT CCA TAT GTT AAT ACT CAA AGG AA-3'), which introduced an NdeI restriction site at the 5' end, and primer P3, which introduced a HindIII restriction site and five histidine codons at the 3' end. The amplified fragments were cloned into the pCold-IV vector (Takara) and introduced into E. coli BL21(DE3)pLysS. The purification of recombinant protein was performed as described above, with some modifications. After the step of nickel-nitrilotriacetic acid chromatography, the eluted protein was dialyzed against 50 mM sodium phosphate buffer (pH 6.4). Furthermore, the protein was applied to a cation-exchange HiTrap S HP column (Amersham Biosciences). Finally, the eluted protein was concentrated and the buffer was exchanged with 50 mM sodium phosphate buffer (pH 7.4).
Methylation assay. Both the 30S and the 50S subunits of E. coli JM109 were prepared as described previously (27). After ultracentrifugation with 10 to 30% sucrose density gradients, the 30S and 50S subunit fractions were collected. The purity of each subunit was checked by denatured agarose gel electrophoresis of the rRNA derived from the material. The methylation assay was carried out at 35°C, as follows. Thirty picomoles of substrate, 30 pmol of His5-NpmA, and 7.5 µCi of S-adenosyl-L-[methyl-3H]methionine (76 Ci/mmol, 1 mCi/ml) were adjusted to 300 µl with methylation buffer (50 mM HEPES-KOH, pH 7.5; 10 mM MgCl2; 100 mM NH4Cl; 5 mM 2-mercaptoethanol). Aliquots were taken at 0, 5, 15, 30, and 45 min and purified with an RNeasy mini kit (Qiagen), according to the instructions provided by the manufacturer. The samples were counted with a scintillation counter.
RNase protection assay. One picomole of [3H]methyl-labeled 16S rRNA was hybridized with 100 pmol of a deoxyoligonucleotide (positions 1421 to 1392 [5'-CAC TCC CAT GGT GTG ACG GGC GGT GTG TAC-3'] and positions 1507 to 1478 [5'-TAC CTT GTT ACG ACT TCA CCC CAG TCA TGA-3']) in 50 µl of hybridization buffer (40 mM morpholineethanesulfonic acid, pH 6.4; 400 mM NaCl; 9 mM EDTA; 80% [vol/vol] formamide) The sample was incubated at 90°C for 10 min, cooled at room temperature for 15 min, and diluted with 450 µl of RNase buffer (10 mM Tris-HCl, pH 7.5; 300 mM NaCl; 5 mM EDTA) containing RNase T1 (Roche). The digestion was performed at 37°C for 1 h. The reaction was stopped by adding 4.5 ml of 10% ice-cold trichloroacetic acid, and the reaction mixture was placed on ice for 10 min. The samples were passed through cellulose nitrate filters. The filters were dissolved in scintillation fluid, and the radioactivity was measured.
Primer extension. One microgram of 16S rRNA extracted from the 30S subunits methylated in vitro was hybridized with 50 pmol of a primer (5'-biotin-CCA ACC GCA GGT TCC CCT ACG G-3') complementary to nucleotides 1530 to 1509 at 65°C for 10 min. The elongation was performed with Transcriptor reverse transcriptase (Roche) at 43°C for 1 h. The cDNA transcripts were analyzed on an 8% polyacrylamide gel containing 8 M urea.
HPLC assay of methylated adenine residue. 16S rRNA was extracted from the 30S subunits of E. coli. Sixty micrograms of extracted 16S rRNA was digested with nuclease P1 (3 U; Wako) and alkaline phosphatase (0.08 U; Takara) in 120 µl of a reaction mixture containing 25 mM HEPES-KOH (pH 7.5) at 37°C for 6 h. The resulting mixture was analyzed by high-performance liquid chromatography (HPLC) with an HRC-ODS column (4.6 mm [inner diameter] by 250 mm; Shimadzu). The solvent system consisted of 5 mM ammonium acetate (pH 5.3) (solvent A) and 30% acetonitrile (solvent B) and was used as follows: 0% to 50% solvent B from 0 to 100 min, 50% to 99% solvent B from 100 to 110 min, and 99% solvent B from 110 to 130 min, with an effluent rate of 600 µl/min at 30°C.
Aminoglycoside binding to 30S subunit. Sixty picomoles of the wild-type or the modified 30S subunits was incubated in 100 µl of dimethylsulfate (DMS) buffer (80 mM sodium cacodylate, pH 7.2; 100 mM NH4Cl; 20 mM MgCl2; 1 mM dithiothreitol; 0.5 mM EDTA) at 42°C for 10 min. Addition of aminoglycosides (final concentration range, 1 µM to 1,000 µM) was followed by incubation at 37°C for 30 min and then on ice for 10 min. DMS (2 µl, 1:6 in ethanol) was added, and the mixture was incubated at 37°C for 10 min. The reaction was quenched by adding 25 µl of stop buffer (1.5 M sodium acetate, 1 M 2-mercaptoethanol). After ethanol precipitation, modified rRNA was obtained by extraction with phenol three times and chloroform twice. Reduction with sodium borohydride and aniline-induced strand scission were performed as described previously (27). A primer extension analysis was carried out as described above.
Nucleotide sequence accession number. The open reading frame of npmA was deposited in the EMBL and GenBank databases through the DDBJ database and has been assigned accession number AB261016.
|
|
|---|
|
View this table: [in a new window] |
TABLE 2. Antimicrobial susceptibilities of parental strain, transconjugant, and transformant
|
![]() View larger version (21K): [in a new window] |
FIG. 1. Schematic presentation of open reading frames (ORFs) in the cloned fragment conferring aminoglycoside resistance. Open reading frames are shown as arrows indicating the transcription orientation. The positions where Tn5 was inserted are indicated by open and closed circles. Mutants with Tn5 insertions shown by open circles demonstrated aminoglycoside resistance, while those indicated by closed circles did not.
|
![]() View larger version (66K): [in a new window] |
FIG. 2. Alignment of deduced amino acid sequences of NpmA with those of KamA and KamB. Chromosomal 16S rRNA methyltransferases (KamA and KamB) were found in aminoglycoside-producing actinomycetes (24, 32). Identical amino acids in all proteins are highlighted with a dark background. Physicochemically similar amino acids are highlighted with a gray background.
|
Antibiotic susceptibilities. The MICs of the aminoglycosides for the NpmA-producing E. coli transformant are shown in Table 2. The introduction of npmA-carrying plasmid pMCL-BE conferred resistance to both 4,6-disubstituted 2-deoxystreptamines, consisting of the kanamycin and gentamicin groups, and 4,5-disubstituted 2-deoxystreptamines, including neomycin and ribostamycin. In addition, NpmA augmented the MIC of apramycin, whose structure is far different from those of the 4,6- and 4,5-disubstituted 2-deoxystreptamines. On the other hand, NpmA did not confer resistance to the non-A-site binders streptomycin and spectinomycin. On the whole, NpmA could confer resistance to various aminoglycosides which bind to the A site of the decoding region in 16S rRNA.
N-terminal sequence of NpmA. As shown in Fig. 2, the exact locations of the N termini of A1408 methyltransferases are still controversial. For example, the N-terminal position of the Kam family of proteins, including KamB and KamC, was previously reported to be position M61, shown in Fig. 2 (22). This fact, however, indicates the lack of a SAM-binding motif, which plays a crucial role in methyltransferase activity among the mature Kam family of enzymes. Most recently, Koscinski et al. reanalyzed the amended amino acid sequences of a Kam family protein and revealed that the SAM-binding motif is perfectly conserved in the missing N-terminal sequences of the Kam family of proteins (24). In this study, in order to determine the exact position of the N terminus in NpmA experimentally, the recombinant NpmA protein was purified from E. coli cells harboring pMCL-BH and was subjected to Edman protein sequencing. The N terminus of NpmA was exactly determined to be MLILK (Fig. 2), although TTG is uncommon as a bacterial initiation codon.
Methylation of 30S subunits by NpmA. E. coli BL21(DE3)pLysS and the pCold-IV expression vector were used for the overexpression and purification of NpmA. E. coli BL21(DE3)pLysS carrying pCold-IV is susceptible to apramycin (MIC, 3.9 µg/ml), while E. coli BL21(DE3)pLysS carrying pCold-NpmA exhibited a very high level of resistance to apramycin (MIC, >1,000 µg/ml) in the microdilution susceptibility test. This result indicated that the histidine-tagged NpmA (His5-NpmA) still has methylation activity and is responsible for apramycin resistance in E. coli BL21(DE3)pLysS. An optimized culture condition yielded 8 mg of purified protein per 1 liter of bacterial culture, and the purified enzyme gave a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with Coomassie brilliant blue staining (Fig. 3A).
![]() View larger version (24K): [in a new window] |
FIG. 3. Purification of NpmA and methylation assays. (A) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of purified His5-NpmA protein. Lanes: M, protein size marker; 1, purified His5-NpmA. (B) Methyl acceptor activities of 30S subunits, 50S subunits, and naked 16S rRNA determined with [3H]SAM and His5-NpmA. The square symbols for the 50S subunits are hidden behind the triangle symbols for 16S rRNA.
|
RNase protection assay. As described above, the in silico analysis indicated that NpmA exhibits amino acid sequence similarity to various chromosomally encoded A1408 16S rRNA methyltransferases of aminoglycoside-producing actinomycetes. This suggested that NpmA would also modify the same position within 16S rRNA, as reported previously (3, 22, 43). To determine the exact position of methylated nucleotide, a hybridization protection study was first carried out with deoxynucleotides that were complementary to a part of the 16S rRNA sequence. Two oligomers from positions 1392 to 1421 and positions 1478 to 1507 were prepared to span the aminoglycoside-binding A-site region within the 16S rRNA. The hybridization with the oligomer from positions 1392 to 1421 served to keep the radioactivity of [3H]methyl-labeled 16S rRNA after RNase T1 digestion, while the oligomer from positions 1478 to 1507 was ineffective in protecting against RNase T1 digestion (Fig. 4A). This finding indicated that the position of the methylated nucleotide is located within the region from residue 1392 to residue 1421 in the 16S rRNA.
![]() View larger version (23K): [in a new window] |
FIG. 4. Nuclease protection assay and primer extension analysis. (A) Nuclease protection assay with [3H]-methyl-labeled 16S rRNA and DNA oligonucleotides (oligo) complementary to the regions from positions 1392 to 1421 or positions 1478 to 1507. The values are the averages of three measurements. Error bars indicate standard deviations. Open bars, undigested; solid bars, digested with RNase T1. (B) Primer extension analysis of methylated 16S rRNA [NpmA(+)] and wild-type 16S rRNA [NpmA(–)]. Dideoxy sequencing lanes (C, A, U, and G) were generated with the amplified PCR products of E. coli 16S rRNA gene as the template. Primer extension termination at position C1409 is indicated by an arrow. (C) Methylation sites in the decoding region in 16S rRNA from E. coli. The exact methylation site by ArmA and RmtB was confirmed at G1405, but that by RmtA, RmtC, and RmtD has not yet been confirmed.
|
HPLC assay of methylated adenine residue. We determined the type of detailed modification by HPLC. When wild-type 16S rRNA was treated with nuclease P1 plus alkaline phosphatase, there was no peak corresponding to 1-methyladenosine (m1A), due to the lack of an innate m1A nucleoside in the 16S rRNA of a K-12-derived E. coli strain (Fig. 5A). On the other hand, the m1A peak was clearly observed when the 16S rRNA methylated by NpmA was analyzed (Fig. 5B). These results clearly demonstrate that NpmA actually methylates the N-1 position of adenosine. Thus, NpmA is an adenine N-1 methyltransferase. Each peak corresponding to m5C, m7G, m3U, and m2G was detected with almost equal intensity between the wild-type and the methylated 16S rRNAs.
![]() View larger version (24K): [in a new window] |
FIG. 5. HPLC analysis of methylated adenine residue. Purified 16S rRNA was completely digested with nuclease P1 and alkaline phosphatase and subjected to HPLC. (A) Wild-type 16S rRNA; (B) 16S rRNA methylated by NpmA. The m1A peak indicates the formation of a methylated adenosine residue at 1408. mAb, milliabsorbance units.
|
![]() View larger version (67K): [in a new window] |
FIG. 6. Footprinting for confirmation of aminoglycoside binding to 30S subunits. The gentamicin, neomycin, and ribostamycin footprints are indicated at the position of G1494 (N-7) in the 16S rRNA. Dideoxy sequencing lanes (lanes C, A, U, and G) were generated with amplified PCR products on the E. coli 16S rRNA gene as the template. Each reaction was performed in the presence of 0, 1, 10, 100, and 1,000 µM aminoglycoside.
|
|
|
|---|
![]() View larger version (52K): [in a new window] |
FIG. 7. Predicted interaction between aminoglycosides and 16S rRNA in the 30S ribosomal subunit. (A) Complex structure of 16S rRNA (black) and 23S rRNA (orange) in the 70S ribosome from E. coli (PDB codes 2AVY and 2AW4) (41). The positions of G1405 (magenta) and A1408 (cyan) are indicated with dots. (B) Enlargement of the region surrounding G1405 and A1408 at the same angle used for panel A. (C and D) Three-dimensional model from the crystal structure of complexes between aminoglycosides (C; gentamicin C1a, PDB code 2ET3) (D; neomycin B, PDB code 2ET4) and nucleotides G1405 and A1408 in the decoding A site (15). The dashed lines indicate probable hydrogen bonds. The figures were rendered with the PyMol program.
|
Additionally, it is speculated that m1A1408 methylation will fundamentally affect the formation of the A1408·A1493 base pair pocket, which is essential for aminoglycoside binding. However, a dynamic conformational change in RNA structure might impair a number of ribosomal innate functions, including decoding, aminoacyl transfer, and translocation. Actually, A1493 participates in codon-anticodon recognition during the tRNA selection step and involves a conformational change from a "tucked-in" form to a "flipped-out" form (28, 31). Although the effect of m1A1408 methylation on the innate rRNA function remains uncertain, it seems unlikely that m1A1408 methylation would be a serious disadvantage for bacterial proliferation, because there is no significant difference in the doubling times between NpmA-producing E. coli and wild-type E. coli strains under culture conditions with both rich and minimal medium compositions (data not shown). A growth competition assay may be required to elucidate the accurate biological cost induced by m1A1408 methylation in bacteria.
The methylation reaction by an innate C1407 16S rRNA methyltransferase, YebU, of E. coli is specific for the 30S subunits and not for the naked 16S rRNA molecule (1). Docking of YebU onto the 30S subunit revealed several contacts between the methyltransferase domain of YebU and ribosomal protein S12 as well as 16S rRNA (21). Hallberg et al. concluded that interactions of YebU with ribosomal protein would explain the substrate specificity seen in YebU (21). Obviously, the accessibility of YebU to the 30S subunit would be supported by the fact that the C1407 position is exposed in the 30S subunit as well as in the 16S rRNA. As expected, the substrate specificity of NpmA is similar to that of YebU (Fig. 3B), and the explanation for this specificity might partially be the same reason suggested for YebU (Fig. 7A and B). A similar substrate specificity was also observed in a part of the aminoglycoside-resistant G1405 16S rRNA methyltransferase group (27). Methylation at an exposed position such as A1408 would occur in the late stage, during the assembly of the 30S subunit.
The G+C content of A1408 16S rRNA methyltransferase genes from aminoglycoside-producing actinomycetes is greater than 70%, whereas that of npmA is 34%. This discrepancy would make it unlikely that the origin of npmA is aminoglycoside producers with high G+C contents. A similar discrepancy was also observed in the case of the G1405 16S rRNA methyltransferases of actinomycetes and pathogenic bacteria. Liou et al. indicated that aminoglycoside producers with low G+C contents, such as Bacillus circulans, which naturally produces butirosin, might be the candidate sources of plasmid-mediated 16S rRNA methyltransferases (27). Although questions remain as to the presence of a 16S rRNA methyltransferase that confers aminoglycoside resistance in the genus Bacillus, the gene products of a putative ABC transporter substrate binding protein (orf7) and a mobilization protein (orf8) located at the 3' end of npmA certainly have relatively low levels of identity to those of Bacillus spp. The detailed characterization of 16S rRNA methyltransferases in aminoglycoside-producing Bacillus spp. demonstrating low G+C contents might provide clues to the identification of the origin of plasmid-mediated 16S rRNA methyltransferases, including npmA.
In conclusion, to our knowledge this is the first time that a novel plasmid-mediated m1A1408 16S rRNA methyltransferase, NpmA, was identified in a panaminoglycoside-resistant E. coli clinical isolate. Indeed, methylation at A964 (pactamycin resistance) (2), G1405 (kanamycin-gentamicin resistance), and A1408 (kanamycin-apramycin resistance) and the loss of methylation at G527 (streptomycin resistance) (33), C1409 (capreomycin resistance) (23), and A1518-A1519 (kasugamycin resistance) (45) have been reported so far to be mechanisms of resistance to 30S subunit-targeting drugs in bacteria. However, these mechanisms have not been fully understood, especially in pathogenic bacteria that tend to be continuously or intermittently exposed to various aminoglycosides in both clinical and livestock farming environments. Further study is warranted to clarify the molecular mechanisms underlying the panaminoglycoside resistance that has been acquired by pathogenic bacteria.
This study was supported by the Ministry of Health, Labor, and Welfare of Japan (grant H18-Shinkou-11). The research activity of J. Wachino was supported by a scholarship for young scientists provided by the Japan Society for the Promotion of Science.
Published ahead of print on 17 September 2007. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»